trending Market Intelligence /marketintelligence/en/news-insights/trending/-nqXyc9a0Hafj0tgBgTxWg2 content esgSubNav
In This List

Collegium terminates opioid drug license agreement with BioDelivery

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Collegium terminates opioid drug license agreement with BioDelivery

Collegium Pharmaceutical Inc. is returning to BioDelivery Sciences International Inc. the U.S. rights to opioid drug Onsolis.

The companies entered a license and development agreement for the drug in May 2016, and have since been collaborating on the transfer of product manufacturing to a new supplier.

Collegium's decision to terminate the license involves its recent license agreement to commercialize Depomed Inc.'s Nucynta.

The termination will be effective March 8, 2018.